Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHIT1 | Q13231 | 16/20 | 0.61 |
| ▸ | CHIA | Q9BZP6 | 9/20 | 0.61 |
| ▸ | KCNH2 | Q12809 | 7/20 | 0.49 |
| ▸ | CHI3L1 | P36222 | 6/20 | 0.45 |
| ▸ | STS | P08842 | 2/20 | 0.45 |
| ▸ | CHI3L2 | Q15782 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18577128 | 1.00 | CHIT1 (0.61) | CHIT1CHIAKCNH2CHI3L1STS | |
| SCHEMBL18589407 | 1.00 | CHIT1 (0.61) | CHIT1CHIAKCNH2CHI3L1STS | |
| SCHEMBL20629078 | 1.00 | CHIT1 (0.61) | CHIT1CHIAKCNH2CHI3L1STS | |
| SCHEMBL18589355 | 0.90 | CHIT1 (0.59) | CHIT1CHIAKCNH2CHI3L1 | |
| SCHEMBL18607913 | 0.90 | CHIT1 (0.59) | CHIT1CHIAKCNH2CHI3L1 | |
| SCHEMBL20747233 | 0.90 | CHIT1 (0.59) | CHIT1CHIAKCNH2CHI3L1 | |
| SCHEMBL18577191 | 0.90 | CHIT1 (0.59) | CHIT1CHIAKCNH2CHI3L1 | |
| SCHEMBL23169723 | 0.87 | CHIA (0.58) | CHIT1CHIAKCNH2CHI3L1CHI3L2 | |
| SCHEMBL18609868 | 0.87 | CHIA (0.58) | CHIT1CHIAKCNH2CHI3L1CHI3L2 | |
| SCHEMBL18589432 | 0.87 | CHIA (0.58) | CHIT1CHIAKCNH2CHI3L1CHI3L2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10208020-B2 | Substituted amino triazoles useful as human chitinase inhibitors | Oncoarendi Therapeutics S.A. (PL) | 2019-02-19 | — | — | US | disclosed |
| US-9944624-B2 | Substituted amino triazoles useful as human chitinase inhibitors | Oncoarendi Therapeutics S.A. (PL) | 2018-04-17 | — | — | US | disclosed |
| US-20170066743-A1 | SUBSTITUTED AMINO TRIAZOLES USEFUL AS HUMAN CHITINASE INHIBITORS | GALAPAGOS NV (BE) | 2017-03-09 | — | — | US | disclosed |
| WO-2017037670-A1 | SUBSTITUTED AMINO TRIAZOLES USEFUL AS HUMAN CHITINASE INHIBITORS | OncoArendi Therapeutics Sp. z o.o. (PL) | 2017-03-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10208020-B2 | Substituted amino triazoles useful as human chitinase inhibitors | CHIA, CHIT1, AADAC | CHIT1 2/4885CHIA 1/4885KCNH2 3882/4885 |
| US-20170066743-A1 | SUBSTITUTED AMINO TRIAZOLES USEFUL AS HUMAN CHITINASE INHIBITORS | CHIA, CHIT1, AADAC | CHIT1 2/4885CHIA 1/4885KCNH2 3882/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.